CN102000202B - 一种治疗硬皮病的中药 - Google Patents
一种治疗硬皮病的中药 Download PDFInfo
- Publication number
- CN102000202B CN102000202B CN201010566363A CN201010566363A CN102000202B CN 102000202 B CN102000202 B CN 102000202B CN 201010566363 A CN201010566363 A CN 201010566363A CN 201010566363 A CN201010566363 A CN 201010566363A CN 102000202 B CN102000202 B CN 102000202B
- Authority
- CN
- China
- Prior art keywords
- radix
- scleroderma
- chinese medicine
- skin
- eupolyphaga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 206010039710 Scleroderma Diseases 0.000 title abstract description 51
- 239000006187 pill Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 241000756943 Codonopsis Species 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 14
- 241000237636 Pheretima Species 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 4
- 210000000582 semen Anatomy 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 2
- 241000723347 Cinnamomum Species 0.000 abstract 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 2
- 241000615160 Codonopsis clematidea Species 0.000 abstract 2
- 241000361919 Metaphire sieboldi Species 0.000 abstract 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 2
- 241000270295 Serpentes Species 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 235000017803 cinnamon Nutrition 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 29
- 239000008280 blood Substances 0.000 description 26
- 208000012322 Raynaud phenomenon Diseases 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 23
- 208000003782 Raynaud disease Diseases 0.000 description 22
- 210000003811 finger Anatomy 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 16
- 231100000915 pathological change Toxicity 0.000 description 16
- 230000036285 pathological change Effects 0.000 description 16
- 210000003238 esophagus Anatomy 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 208000034189 Sclerosis Diseases 0.000 description 14
- 206010042953 Systemic sclerosis Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 12
- 241001530038 Pantherophis obsoletus Species 0.000 description 11
- 201000009594 Systemic Scleroderma Diseases 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 210000001835 viscera Anatomy 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 206010003694 Atrophy Diseases 0.000 description 9
- 230000037444 atrophy Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 206010040882 skin lesion Diseases 0.000 description 9
- 231100000444 skin lesion Toxicity 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000006188 syrup Substances 0.000 description 9
- 235000020357 syrup Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000010792 warming Methods 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 8
- 208000006820 Arthralgia Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 206010027982 Morphoea Diseases 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 208000002815 pulmonary hypertension Diseases 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- 206010048768 Dermatosis Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000000185 Localized scleroderma Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000007664 blowing Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000000245 forearm Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000008855 peristalsis Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 208000037920 primary disease Diseases 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 208000002720 Malnutrition Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 238000005202 decontamination Methods 0.000 description 5
- 230000003588 decontaminative effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 235000000824 malnutrition Nutrition 0.000 description 5
- 230000001071 malnutrition Effects 0.000 description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 201000002829 CREST Syndrome Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 208000018631 connective tissue disease Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 210000002832 shoulder Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000216 vascular lesion Toxicity 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010002027 Amyotrophy Diseases 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 206010047163 Vasospasm Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 208000008494 pericarditis Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- -1 stir Chemical compound 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 210000004876 tela submucosa Anatomy 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 235000006793 Artemisia stelleriana Nutrition 0.000 description 2
- 244000252230 Artemisia stelleriana Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000003367 Hypopigmentation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000283956 Manis Species 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 206010035669 Pneumonia aspiration Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 206010039163 Right ventricular failure Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 201000009408 aspiration pneumonitis Diseases 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000006413 coastal sagewort Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002580 esophageal motility study Methods 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 230000003425 hypopigmentation Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 240000003211 Corylus maxima Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000024136 Limited systemic sclerosis Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000029301 Mastication disease Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000000023 Osteosclerosis Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000736919 Pelodiscus sinensis Species 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003476 anti-centromere Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000004755 lingual frenum Anatomy 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000037377 skin turgor Effects 0.000 description 1
- 230000033398 smooth muscle atrophy Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002037 soft tissue calcification Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及治疗硬皮病的中药,可有效解决硬皮病的治疗问题,该中药是由以下组分制成:党参100-140g、黄芪140-180g、鹿角霜70-90g、丹参70-90g、红花50-70g、熟地70-90g、桂枝35-45g、肉桂35-45g、炙麻黄35-45g、炙土元50-70g、地龙50-70g、乌稍蛇50-70g、炒白介子35-45g、甘草20-28g;其中,将党参、炙土元、鹿角霜、地龙、红花、炒白芥子、乌稍蛇、甘草分别粉碎,过300目筛,混合均匀成超微细粉;再将熟地、桂枝、肉桂、炙麻黄、丹参、黄芪6味药加其重量和的水6-8倍,煎煮二次,每次1.5小时,合并煎液,浓缩至相对密度为1.20-1.30的浸膏;将上述细粉和浸膏混合在一起,和成药坨,再制成药丸,包装,本发明原料丰富,制备工艺简单,易生产,成本低,服用方便,疗效好,是治疗硬皮病药物上的创新。
Description
一、技术领域
本发明涉及医药,特别是一种治疗硬皮病的中药。
二、背景技术
硬皮病现称系统性硬化症。顾名思义,就是皮肤变硬的疾病。皮肤的改变是系统性硬化症的标志性症状。但病变程度差别很大,轻者仅有局部皮肤的硬化和钙化,严重者可出现全身广泛性皮肤硬化增厚。典型的皮肤损害依次经历肿胀期、浸润期和萎缩期三个阶段。病变呈对称性,病变多由手指逐渐向近端扩展,病变皮肤与正常皮肤的界限不清,临床上以局限性或弥漫性皮肤增厚和纤维化为特征,并累及心、肺、肾、消化道等内脏器官的结缔组织病。各年龄均可发病,但以20-50岁为发病高峰。女性发病率约为男性的3-4倍。硬皮病是一种结缔组织病,属慢性病,虽然局限性硬皮病不影响生命,但患者心理上精神上,则受到严重的刺激,若不及时治疗,可能会毁容,或者影响到正常的肢体活动。严重会影响内脏功。系统性硬皮病则直接影响健康。甚至危及生命,如何治疗硬皮病,提高生活质量,是近几年来摆在医务人员面前的新课题。
三、发明内容
针对上述情况,为克服现有技术之缺陷,本发明目的就是提供一种治疗硬皮病的中药,可有效解决硬皮病的治疗问题。
本发明解决的技术方案是,硬皮病从中医理论来看其发病主要是寒凝经脉,气血运行受阻,或脾肾阳虚,阴阳失调,肌肤失于温煦,日久肌肉蒌缩不用,坚硬如皮革,寒凝血脉,痹阻不通而致气滞血瘀,外邪乘虚而入,造成皮肤局部或内脏组织硬化。故“寒凝血脉,气滞血瘀”是本病病机之关健。故应以补气通阳,活血化瘀,通经活络为本病治疗的原则。方中党参,黄芪,鹿角霜补气通阳,温补脾肾,用为君药;红花,丹参,熟地,桂枝,肉桂炙麻黄,活血化瘀,宣肺通阳用为臣药;炙土元,地龙,穿山甲,乌稍蛇,搜风祛湿,通经活络,用为佐药;炒白介子消肿散结,甘草调和诸药用为使药。综合全方,药精功专,理法方药,环环相扣,共奏补气通阳,温补脾肾,活血化瘀,通经活络之功能,故此,根据中药学原理,本发明中药是由以下药物制成:党参100-140g、黄芪140-180g、鹿角霜70-90g、丹参70-90g、红花50-70g、熟地70-90g、桂枝35-45g、肉桂35-45g、炙麻黄35-45g、炙土元50-70g、地龙50-70g、乌稍蛇50-70g、炒白介子35-45g、甘草20-28g;其中,将党参、炙土元、鹿角霜、地龙、红花、炒白芥子、乌稍蛇、甘草分别粉碎,过300目筛,混合均匀成超微细粉;再将熟地、桂枝、肉桂、炙麻黄、丹参、黄芪6味药加其重量和的水6-8倍,煎煮二次,每次1.5小时,合并煎液,浓缩至相对密度为1.20-1.30的浸膏;将上述细粉和浸膏混合在一起,和成药坨,再制成药丸,包装。
本发明本发明原料丰富,制备工艺简单,易生产,成本低,服用方便,疗效好,是治疗硬皮病药物上的创新。
四、具体实施方式
以下结合实施例对本发明的具体实施方式作详细说明。
实施例1:
本发明在具体实施中,是由以下药物制成:党参120g、黄芪160g、鹿角霜80g、丹参80g、红花60g、熟地80g、桂枝40g、肉桂40g、炙麻黄40g、炙土元60g、地龙60g、乌稍蛇60g、炒白介子40g、甘草24g;其中,将党参、炙土元、鹿角霜、地龙、红花、炒白芥子、乌稍蛇、甘草分别粉碎成超微细粉,过300目筛,混合在一起,使其成为粒径≤10μm的细粉;将熟地、桂枝、肉桂、炙麻黄、丹参、黄芪6味药加其重量和的8倍的水(3520ml)煎煮1.5小时,过滤得煎液,再在药渣中加入原6味药重量和6倍的水(2640ml)煎煮1.5小时,过滤得煎液,合并两次煎液,浓缩至密度为1.25的浸膏;将上述细粉和浸膏混合在一起,和成药坨;然后由制丸机制成中药丸,再将中药丸置于烘箱中80℃干燥至水分小于5%后,取出,将干燥的丸粒置糖衣锅内转动锅,加入适量的糖浆,搅拌均匀,待丸粒表面呈毛刺状且丸心润透时,加入适量的滑石粉,搅拌均匀,使滑石粉全部裹附于丸粒表面,再加糖浆,加滑石粉,如此反复,用吹风机将丸粒吹干,然后停止吹风,再加入糖浆,搅拌,使丸粒表面均匀一致为准。待丸粒表面略干时,再加热吹风将丸吹干,然后加入蜡粉,转动摩擦至丸表面极为光亮为止,出锅,放置净容器中,室温下将药丸按60g/瓶分装,在标签上准确清晰地加盖批号后贴签,即得。
实施例2
本发明在具体实施中,还可由以下药物制成:党参100g、黄芪140g、鹿角霜70g、丹参70g、红花50g、熟地70g、桂枝35g、肉桂35g、炙麻黄35g、炙土元50g、地龙50g、乌稍蛇50g、炒白介子35g、甘草20g;其中,将党参、炙土元、鹿角霜、地龙、红花、炒白芥子、乌稍蛇、甘草分别粉碎成超微细粉,过300目筛,混合在一起,使其成为粒径≤10μm的细粉;将熟地、桂枝、肉桂、炙麻黄、丹参、黄芪6味药加其重量和的8倍的水煎煮1.5小时,过滤得煎液,再在药渣中加入原6味药重量和6倍的水煎煮1.5小时,过滤得煎液,合并两次煎液,浓缩至密度为1.20的浸膏;将上述细粉和浸膏混合在一起,和成药坨;然后由制丸机制成中药丸,再将中药丸置于烘箱中80℃干燥至水分小于5%后,取出,将干燥的丸粒置糖衣锅内转动锅,加入适量的糖浆,搅拌均匀,待丸粒表面呈毛刺状且丸心润透时,加入适量的滑石粉,搅拌均匀,使滑石粉全部裹附于丸粒表面,再加糖浆,加滑石粉,如此反复,用吹风机将丸粒吹干,然后停止吹风,再加入糖浆,搅拌,使丸粒表面均匀一致为准。待丸粒表面略干时,再加热吹风将丸吹干,然后加入蜡粉,转动摩擦至丸表面极为光亮为止,出锅,放置净容器中,室温下将药丸按60g/瓶分装,在标签上准确清晰地加盖批号后贴签,即得。
实施例2
本发明在具体实施中,还可由以下药物制成:党参140g、黄芪180g鹿角霜90g、丹参90g、红花70g、熟地90g、桂枝45g、肉桂45g、炙麻黄45g、炙土元70g、地龙70g、乌稍蛇70g、炒白介子45g、甘草28g;其中,将党参、炙土元、鹿角霜、地龙、红花、炒白芥子、乌稍蛇、甘草分别粉碎成超微细粉,过300目筛,混合在一起,使其成为粒径≤10μm的细粉;将熟地、桂枝、肉桂、炙麻黄、丹参、黄芪6味药加其重量和的8倍的水煎煮1.5小时,过滤得煎液,再在药渣中加入原6味药重量和6倍的水煎煮1.5小时,过滤得煎液,合并两次煎液,浓缩至密度为1.30的浸膏;将上述细粉和浸膏混合在一起,和成药坨;然后由制丸机制成中药丸,再将中药丸置于烘箱中80℃干燥至水分小于5%后,取出,将干燥的丸粒置糖衣锅内转动锅,加入适量的糖浆,搅拌均匀,待丸粒表面呈毛刺状且丸心润透时,加入适量的滑石粉,搅拌均匀,使滑石粉全部裹附于丸粒表面,再加糖浆,加滑石粉,如此反复,用吹风机将丸粒吹干,然后停止吹风,再加入糖浆,搅拌,使丸粒表面均匀一致为准。待丸粒表面略干时,再加热吹风将丸吹干,然后加入蜡粉,转动摩擦至丸表面极为光亮为止,出锅,放置净容器中,室温下将药丸按60g/瓶分装,在标签上准确清晰地加盖批号后贴签,即得。
上述药物,其中:
党参:洗净、切片、干燥,具有补中益气,健脾益肺的功效,用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴;
黄芪:去杂质、洗净、晒干、切片。功效:补气固表,利尿托毒,排脓,敛疮生肌。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿黄芪圆片,痈疽难溃,久溃不敛,血虚痿黄,内热消渴。
鹿角霜:拣去杂质,斫成小块,晒干。温肾助阳,收敛止血。用于脾肾阳痿,食少吐泻,白带,遗尿尿频,崩漏下血,痈疽痰核。
丹参:洗净、切片、干燥,具有活血祛瘀、养血安神、凉血消肿的功效。用于淤血、头、胸、胁、腹疼痛,癥瘕积聚,月经不调、痛经闭经,关节痹痛,跌打瘀肿,疮疡肿毒,丹疹疥癣。
红花:具有活血祛瘀,散郁开结,活血通经。主治:痛经,闭经,瘀滞腹痛,胸痹心痛,血积癥瘕,关节疼痛
熟地:具有补血滋阴作用,可用于血虚萎黄,眩晕,心悸失眠,月经不调,崩漏等症,亦可用于肾阴不足的潮热骨蒸、盗汗、遗精、消渴等症,
桂枝:功效:发汗解表,温通经脉,散寒止痛。主治:感冒风寒,发热恶寒;寒湿痹证,肢节酸痛;胸痹痰饮;腹中寒痛,闭经痛经;小便不利等病症。
肉桂:功能主治:补火助阳,引火归源,散寒止痛,活血通经。用于阳痿、宫冷、心腹冷痛、虚寒吐泻、经闭、痛经、温经通脉。
炙麻黄:具有发汗解表,宣肺平喘,利水。用于感冒风寒及麻疹透发不畅,风疹身痒等症。
炙土元:(又称土鳖虫)将烫死并洗净后的土元,置烘箱内烘干或放在锅内用文火炒、拌(温度控制在50~C左右1至虫体的足尖微粘锅铲时,将虫体放在铁线网内,架在灶上,借灶堂中的余热将虫体烘干。有止痛,结筋骨,破瘀血,续筋骨之功效。用于筋骨折伤,瘀血经闭,症瘕痞块。
地龙:去杂质、洗净、干燥。功能清热平肝、熄风止痉、平喘、利尿、通络除痹。主治高热烦躁、惊痫抽搐、肺热喘咳、热结尿闭、痹痛肢麻、半身不遂,以及疮疡肿毒等证。
乌稍蛇:去杂质、洗净、干燥。功效:具有抗炎和镇静、镇痛作用。主治:祛风湿、通经络、熄风止痉,止痒解毒。主治风湿顽痹,麻木拘挛,中风口渴,风疹疥癣,癗疬恶疮。
炒白芥子:洗净、晒干、打下种子、除去杂质,照清炒法炒至深黄色有香辣气。温肺豁痰利气,散结通络止痛。用于寒痰喘咳,胸胁胀痛,痰滞经络,关节麻木、疼痛,痰湿流注,阴疽肿毒。
甘草:去杂质、洗净、干燥。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
硬皮病从中医理论来看其发病主要是寒凝经脉,气血运行受阻,或脾肾阳虚,阴阳失调,肌肤失于温煦,日久肌肉蒌缩不用,坚硬如皮革,寒凝血脉,痹阻不通而致气滞血瘀,外邪乘虚而入,造成皮肤局部或内脏组织硬化。故“寒凝血脉,气滞血瘀”是本病病机之关健。故应以补气通阳,活血化瘀,通经活络为本病治疗的原则。方中党参,黄芪,鹿角霜补气通阳,温补脾肾,用为君药;红花,丹参,熟地,桂枝,肉桂炙麻黄,活血化瘀,宣肺通阳用为臣药;士鳖虫,地龙,穿山甲,乌稍蛇,搜风祛湿,通经活络,用为佐药;炒白介子消肿散结,甘草调和诸药用为使药。
由上述药物配伍,互相支持,具有补脾益肾,宣肺温经,活血化瘀,通经活络之功,有效用于局限性、系统性硬皮病的治疗,服用方便、简单、效果好,并由临床资料得到了充分证明,具体有关本发明的临床资料如下:
A、硬皮病的临床表现:
1、皮肤表现:早期手、指肿胀,也可累及前臂、足、下肢和面部,但下肢受累较少。肿胀期可持续几星期、几个月,甚至更长时间。水肿为可凹性或不可凹性,可伴有红斑。皮肤病变由肢体远端起始向近端进展。皮肤逐渐变硬、增厚,最后紧贴于皮下组织(硬化期)。
皮肤病变可分为水肿、硬化和萎缩3期。
(1)水肿期(edematous phase):表现为皮肤变厚、绷紧、皱纹消失,呈非凹陷性或可凹陷性水肿,颜色苍白或淡黄,皮温偏低,出汗减少,皮表可出现小的皲裂,指尖脂肪垫消失。在局限型皮肤病变患者早期水肿出现在手指、手背和面部,以后向上肢、颈、肩等处蔓延,弥漫型者则往往由躯干部先发病,然后向周围扩展。此期可持续数月。
(2)硬化期(indurative phase):皮肤增厚变硬,发生纤维化,手指、手背发亮绷紧,早期皮肤可发红,表面有蜡样光泽,不出汗,毛发稀少,皮肤不易捏起。面部皮肤受累时可出现面部绷紧,表情固定,唇变薄,口周出现放射性沟纹,张口困难,鼻端变尖,手指渐变细,末节手指变尖变短。可出现溃疡。可产生手指屈伸受限。胸部紧束感,患处皮肤可发生色素沉着和色素减退,毛发稀少,皮肤改变可局限于手指、足趾、手、足和面部,可向前臂扩展,亦可从胸背部开始,向周围扩展,累及上臂、肩、腹和腿。通常在发病3年内皮损范围和严重程度达高峰。
(3)萎缩期(atrophic phase):皮肤萎缩变薄如羊皮纸样,有时皮下组织及肌肉亦可发生萎缩及硬化,皮纹消失,毛发脱落,皮肤光滑而细薄,紧贴于骨骼,指端及关节处易发生顽固性溃疡,亦可出现毛细血管扩张,以及皮下组织钙化。以上为硬皮病的典型皮肤损害及过程,除Sine硬皮病无皮肤表现外,其他各型均可出现,这三期之间并没有明显界限,而是渐进的皮肤病变过程。
皮肤受累的测量方法:
对受累皮肤的范围和程度进行定期检测,将有助于确定疾病的分期和判断皮肤病变的进程。改良的Rodnan皮肤厚度积分法是一种简化半定量皮肤评分法。具体方法是:检查者分别捏起以下17个部位的皮肤:面部、前胸、腹部,左、右上臂、左、右前臂、左、右手、左、右手指、左、右大腿、左、右小腿、左、右足。对每一个部位按评分标准进行评分:皮肤厚度正常为0分;皮肤轻度增厚为1分;皮肤明显增厚为2分;皮肤极度增厚为3分。然后再将这17个部位的积分累加。此法比较准确可靠,可用于临床估测病情及进行观察研究。
2、雷诺现象
(1)硬皮病的血管病变:几乎所有硬皮病患者均有雷诺现象,提示血管病变是硬皮病发病的基础。当病人遇冷或情绪激动时,会出现手足指(趾)皮肤毛细血管前动脉和动静脉分流的关闭引起皮肤苍白、继而发绀的变化。刺激结束(转暖)后,血管痉挛解除,皮肤转为潮红,伴麻木、烧灼、刺痛感,通常需10~15min,指(趾)变为正常颜色或呈斑状。
(2)原发性雷诺现象(primary Raynauds phenomenon):雷诺现象分为两类:原发性(特发性)雷诺现象,也叫雷诺病(Raynauds disease)和继发性雷诺现象(secondary Raynaudsphenomenon)。前者病因不明,后者则继发于某些疾病或已知原因的血管痉挛。
对普通人群的调查显示4%~15%的人有雷诺现象的表现,他们中多数人无血管结构的改变或组织缺血性损害(原发性雷诺现象)。有雷诺现象的病人50%为原发性。典型的原发性雷诺现象开始于青少年,20~40岁多见,女性多于男性。原发性雷诺现象患者在其他方面基本正常,症状出现在指(趾),呈对称分布。
对医生而言,重要的问题是要确定雷诺现象是原发的还是硬皮病的首发症状,两者的鉴别:如有雷诺现象者不具有指凹陷、溃疡、坏疽,甲皱毛细血管和血沉正常,抗核抗体阴性,则很少可能为硬皮病。如甲皱毛细血管袢增大和(或)减少和消失,提示患者有结缔组织病如硬皮病。
(3)雷诺现象与硬皮病:硬皮病病人90%有明显雷诺现象,雷诺现象的出现是血管痉挛和指动脉结构异常的表现。与正常人比,硬皮病病人有营养不良,以及在低温环境下经温度调节流向皮肤血流的反应过度。同样在环境转暖时,解除血管收缩,恢复局部血流的反应亦延迟。
3.肌肉、关节及骨病变
(1)肌肉病变:硬皮病患者常表现明显的肌痛、肌无力,这可以是硬皮病最早出现的非特异性症状。晚期还可出现肌肉萎缩。一方面是由于皮肤增厚变硬限制关节的运动功能,造成肌肉失用性萎缩。弥漫型硬皮病这种情况可发生于任何关节,但手指、腕、肘关节较多见。另一方面也与从肌腱向肌肉蔓延的纤维化有关。还有的是继发于药物治疗,如皮质类固醇和青霉胺的使用。当硬皮病与多发性肌炎或皮肌炎重叠时病人可有明显近端肌无力,血清肌酸磷酸激酶(CPK)持续增高。肌电图显示多相电位增加,波幅和时限降低,无插入性应激性和纤维颤动。肌肉组织活检呈炎性改变,炎细胞浸润、肌纤维变性、萎缩或纤维化。
(2)关节炎:关节炎多发生在手指、腕、膝、踝等四肢关节,关节痛亦可以是硬皮病早期出现的非特异性症状。病人常有较明显的关节疼痛和晨僵,疼痛可从关节沿肌腱涉及上臂及小腿部肌肉。腕、踝、肘、膝关节活动时疼痛加重,并可出现较粗糙的摩擦音,这是因腱鞘和邻近组织的纤维化及炎症所致。这种摩擦音多见于弥漫型硬皮病,提示预后不佳。约29%的病人可出现侵蚀性关节病变。
(3)骨病变:X线骨骼检查可发现骨质疏松,骨硬化,骨破坏,骨萎缩,肢端、指丛骨吸收造成指骨变细变短,软组织钙化。关节间隙变窄、骨侵蚀及关节强直较少见。
4.消化系统病变80%~90%的硬皮病患者可出现消化系统受累。也可是硬皮病的首发症状。
(1)口咽部:开口受限,口腔黏膜干燥、硬化,舌乳头消失,舌肌萎缩,舌不能伸出口外,牙周疾患导致患者咀嚼困难,牙齿脱落及营养不良。一股上咽部功能不受影响,除非纹状的咽肌受累,出现肌炎或神经肌肉病变。此时,食物经口进入食道将有咽下困难,患者吞咽液体食物时出现呛咳,经鼻反流,头、肩前屈均可提示原发性肌病或神经疾患。
(2)食管:80%~90%患者有食管功能异常,常见症状是吞咽困难、食物反流及营养不良。吞咽困难常表现为患者吞咽固体食物后感觉食物在食管某一部位有粘住感,饮水后方可缓解。病人食管蠕动减弱可出现饱胀感以及食物急性嵌塞。
由于病人远端食管的原发性及继发性蠕动减弱或消失,食管下段括约肌压力下降,出现反流性食管炎。病人可有胸骨后烧灼痛、恶心,进餐后或平卧时反流症状加重,在局限型及弥漫型皮肤病变性硬皮病均可出现食管反流及食管炎。
由于固体食物在胃内滞留而延迟排空加重了食管反流并导致饱胀、恶心、呕吐。为避免出现这些症状患者经常减少进食,导致体重下降,营养不良。
食管疾患的并发症包括:食物误吸入肺引起吸入性肺炎,不明原因的咳嗽、声嘶、不典型胸痛、局部念珠菌感染等。
只有当患者有食管蠕动减弱、胃酸排空延迟时,才会出现食管炎,此时可行钡餐检查、内镜检查、食管测压检查以助确定病变的性质和程度。钡餐检查可见食管蠕动减弱或消失、食管扩张,下1/3可见狭窄。内镜检查显示黏膜有不同程度糜烂和变薄,组织病理检查显示食管平滑肌萎缩,由纤维组织所代替,黏膜下层和黏膜固有层纤维化。食管测压检查可显示食管收缩力减弱。
一股有食管病变者常伴有明显的雷诺现象。
(3)胃:较少受累,但患者易有饱胀感,胃窦部血管扩张可以是硬皮病患者胃肠道出血的原因之一。
(4)小肠:由于肠壁纤维化和平滑肌萎缩,导致小肠蠕动异常。通常表现为反复发作的轻度腹痛、腹泻、体重减轻和营养不良。营养不良和腹泻是由于肠内容物滞留,细菌过度繁殖而引起的吸收障碍所致。严重时患者可出现慢性假性梗阻,表现为腹痛、腹胀和呕吐。
在进展性肠病变的患者偶见肠囊性积气,此时肠内气体可胀入肠壁,偶可胀入腹腔,表现很像肠管破裂。
(5)结肠:结肠各段均可受累。硬皮病患者结肠张力下降,少有腹泻,常见便秘、下腹胀及便嵌塞。由于硬皮病患者肠壁肌萎缩,其特有的无症状性广口憩室常发生在横结肠和降结肠部位,若肛门括约肌受累,可出现直肠脱垂和大便失禁。
(6)肝脏:肝脏病变并不常见,但原发性胆汁性肝硬化的出现往往都与CREST综合征有关。
总之,引起硬皮病消化系统病变的主要原因是神经支配的改变、平滑肌的萎缩和黏膜下层的纤维化。硬皮病肠道的最早损害是神经支配的缺陷。这种缺陷类似于继发于微血管病的神经组织缺血性损害。晚期胃肠道平滑肌萎缩和黏膜下层及肌层的纤维化成为主要的病理变化。这种神经缺陷和纤维化共同导致消化道不可逆性功能障碍。
5.肺病变硬皮病患者肺受累很常见,与心脏受累常相伴出现,是患者的主要死因。最早的症状是活动后气短;后期表现为无痰性干咳。胸痛通常不是由硬皮病性肺病变所引起,而是与骨骼肌肉痛、反流性食管炎、胸膜炎或心包炎有关。硬皮病患者同时存在肺间质纤维化和肺动脉血管病变,但以一种病理改变为主,肺间质纤维化在抗Scl-70抗体阳性的弥漫型硬皮病患者表现比较明显,且较严重,而肺血管病变及肺动脉高压是CREST综合征患者的主要肺部表现。硬皮病患者病程中亦可出现继发于食管病变而导致的吸入性肺炎,由呼吸肌无力而导致的呼吸衰竭、肺出血、胸膜反应、气胸、肺动脉高压所致右心衰竭等。
用特异和敏感的方法检测约80%的患者有肺功能异常。绝大部分肺病变并没有明显的临床症状,直到肺纤维化加重,出现肺动脉高压时才表现出症状。此时肺功能检测显示限制性通气障碍,可有肺容积减小[如,用力肺活量(FVC)减少]或一氧化碳弥散量下降,后者可反映气体交换功能受损,由肺间质纤维化或肺血管病变引起,如果其下降低于预定值的40%,或有一氧化碳弥散量快速下降和(或)肺容量快速下降则提示预后不良。
由嗜中性肺泡炎所致的肺间质纤维化可经CT和(或)支气管肺泡灌洗法来检测。X线胸片检查相对不敏感,但如有异常可显示:双侧肺间质纹理增强,肺实质下叶有网状一结节状改变。当存在活动性肺泡炎,经高分辨CT检查,可有“毛玻璃”样改变。支气管肺泡灌洗液检查显示细胞增多。患者可表现为明显的呼吸困难和一氧化碳弥散量降低肺动脉血管病变出现肺动脉高压是硬皮病控制中最棘手的问题,在出现严重的不可逆的肺动脉高压前,临床常很难发现。利用二维超声心动图进行非创性检测有助于早期发现肺动脉高压的存在。
6.心脏病变可表现为心肌炎、心包炎或心内膜炎,各种心脏病的明显临床征象均提示预后不良。
硬皮病心脏受累的主要症状包括活动后气短、心悸、胸部不适以及心包炎、充血性心力衰竭、肺动脉高压和心律失常所引起的相应临床表现,心脏表现的出现与抗Scl-70抗体或抗RNA多聚酶抗体的存在有关。
硬皮病病人可因肺部损害导致肺源性心脏病,引起右心衰竭。无肺纤维化表现的单纯性肺动脉高压症不多见,几乎仅见于CREST综合征。
凡具有上述症状者,均作为选择病例的标准,并给予治疗。
B、诊断标准:
1、硬皮病的中医诊断标准:
参照1986年中华全国中医学会外科学会修订的《硬皮病中医诊断疗效评定标准》和国家中医管理局发布的《中医病证的诊断疗效标准》。
(1)局限性硬皮病
①主证:局部皮肤发硬,肿胀,呈黄白色或象牙色,可呈点滴状、斑片状、带状分布,局部不出汗,后期皮肤萎缩,色素减退。
②周围有淡红或紫红色斑块,皮肤不长毳毛。
③发生于任何年龄,女性多于男性
(2)系统性硬皮病
①主证:皮肤呈非凹陷性肿胀,皱纹消失,面部皮肤绷紧,缺乏表情,呈假面具样,鼻子变尖,口唇变薄,口张不大,食道吞咽硬物困难,手指变硬,呈半屈曲状,指端变细,甚至溃疡。
②两手、前臂、躯干局部皮肤硬化,色素异常。
③累及食道、胃肠,心肾,肺等内脏,功能异常。
④出现雷诺氏症现象。
多发生于20-50岁之间,女性大于男性
中医辩证标准
按照中医皮肤病学辩证分型原则进行:寒凝经脉证,气滞血瘀证,脾肾阳虚证,皮肤肿胀变硬,皮纹消失,呈非凹陷肿胀,有蜡样光泽,捏起困难,无汗,皮肤干燥,或内脏受损,舌质淡红或紫暗,苔薄白,脉沉或濡。
2、硬皮病的西医诊断标准:
参照2001年4月出版的《临床皮肤病学》硬皮病诊断标准。
(1)局限性硬皮病
a局部皮肤象牙色浮肿,硬化
b病变活动期周围有淡红色晕
c皮肤织组病理检查有助于确诊
(2)系统性硬皮病
1)主证
①皮肤症状
a、初期:手背、上眼睑不明原因的浮肿,以及皮肤对称性弥漫性浮肿性硬化。
b、晚期:皮肤硬化以及手指的屈曲性挛缩。
②四肢症状;
a、雷诺现象《肢端动脉痉挛现象》。
b、指,趾未端溃疡或瘢痕形成。
③关节症状:多发性关节痛或关节炎。
④胸部症状:肺纤维化。
⑤消化道症状:食道下部扩张及收缩功能低下。
2)病理所见
①前臂伸侧皮肤活组织检查,显示本病特有的胶原纤维肿胀或纤维化。
②血管壁显示上述类似变化。
疑诊
①前臂伸侧皮肤活组织检查,显示本病特有的胶原纤维肿胀或纤维化。
②除主要症状中之皮肤症状以外的其余4项症状中具有二项,并能排除其它结缔组织病。
确诊
①上述疑诊病例中具有病理所见的(1)和(2)者
②主要症状中有3项以上者
参考事项:硬皮病
一般与下述各项关系甚密切:
①多为女性;
②不规则发热;
③舌系带明显缩短;
④弥漫性色素沉着;
⑤面、颈部及手掌呈斑纹状,多发性毛细血管扩张。
⑥实验室检查所见;
a、类风湿因子阳性,有抗Scl-70抗体阳性,抗着丝点抗体阳性。
b、血沉快,Y球蛋白上升,白细胞增多。
c、指骨未端骨质吸收或软组织钙沉着。
硬皮病的症状体征:
(一)、分类
1)局限性硬皮病包括硬斑病、带状硬皮病、点滴状硬皮病、片状硬皮病。
2)系统性硬化症包括肢端硬皮病、弥漫性硬皮病、CREST综合征(包括肢端硬化和毛细血管扩张,钙质沿积,雷诺氏现象,食管蠕动异常症状,此为系统性硬化的一个类型,予后较好。)
(二)、症状和体征
1.局限性硬皮病
(注意:部分局限性硬皮病可以转化为系统性硬皮病,两者没有绝对界限!)
(1)硬斑病:多发生在腰、背部,其次为四肢及面颈部,表现为圆形、椭圆形或不规则形的水肿性斑片,初呈淡红或紫红,经数周或数月逐渐扩大硬化,颜色变为淡黄色或象牙色,局部无汗、毛发脱落,数年后转化为白色或淡褐色萎缩性疤痕。皮肤活检符合硬皮病改变。
(2)带状硬皮病:好发于儿童和青年,女性多于男性,病变沿肋间和一侧肢体呈带状分布,可为单条或数条,病变演变过程同硬斑病。
(3)点滴状硬斑病:多发于颈、胸、肩背等处,约绿豆至五分硬币大小,呈集簇性线状排列,其演变过程似硬斑病
2.肢端硬皮病与弥漫性硬皮病
肢端硬皮病有雷诺氏现象,皮损从远端向近端发展,躯干、内脏累及少,病程进展慢,预后好;弥漫性硬皮病病变由躯干向远端扩展,雷诺现象少,内脏受累多。病情重,病变进展快,予后差。
(1)雷诺氏现象:为多数患者的首发症状,表现为指(趾)端遇冷或情绪波动时出现发白→青紫→变红三相改变,经保暖后可缓解
(2)皮肤:病变过程可分为水肿,硬化和萎缩三期。
系统性硬化症是一个累及多系统的自身免疫病,除有皮肤特征性改变外,还可累及内脏,其中最常受累的是消化道,几乎整个消化道均可受累,比如食管、胃、肠道均可发生病变,其次是肺脏,可发生不同程度的间质纤维化,另外,心脏、肾脏、肝脏、甲状腺、神经系统也可受累
凡具有上述病状,确定为硬皮病患者。
3、治疗方案:患者口服本发明中药,每日三次,每次8g,,饭后半小时服用,两个月为一个疗程,两个疗程统计治疗结果。
4、疗效评定标准:
临床治愈:局部皮肤变软,颜色变淡或正常皮肤,皮肤可提起,毳毛长出,系统性硬皮病内脏功能较大恢复。
有效:局部皮损被控制,肤色变淡,皮损皮肤可以掐起,雷诺证现象消失或基本消失,食道功能有改善。
显效:局部皮损轻度变软,皮损有皱折,肤色改变,食道功能较前稍有改善。
无效:局部皮损及内脏组织功能无改善。
5、统计学处理:
经临床实践,2年内经对60例服用本发明的结节病患者统计,男21例,女39例,年龄14~63岁,临床症状除呼吸道症状外,有发热、关节肿痛、皮疹、视力异常、头痛、乏力等,胸部X线及CT示19例双肺门肿大,1例单侧肺门肿大伴纵隔淋巴结肿大。用泼尼松40~60mg/d治疗,连用2~3个月后逐渐减量,T淋巴细胞转化率由治疗前0.54±0.18升高至0.69±0.23;SACE由(69.8±12.6)U/L下降至(38.2±12.6)U/L,IgG由(21.30±4.18)g/L下降至(16.80±4.23)g/L,同时症状明显缓解。
具体治疗情况如下表:
病例数 治愈 有效 显效 无效 有效率 |
60人 16(26%) 29(48.3%) 13(21.6%) 2(3.5%) 96.5% |
在上述治疗过程中,无发现有不良反应,用药安全。
6、结论
由上述情况证明,本发明对硬皮病的治疗有特效,且对硬皮病患者的免疫功能有一定的调节作用,服用方便,安全,成本低,易生产,有突出的临床意义,是治疗硬皮病药物上的创新,经济和社会效益巨大。
Claims (2)
1.一种治疗硬皮病的中药,其特征在于,该中药是由党参100-140g、黄芪140-180g、鹿角霜70-90g、丹参70-90g、红花50-70g、熟地70-90g、桂枝35-45g、肉桂35-45g、炙麻黄35-45g、炙土元50-70g、地龙50-70g、乌梢蛇50-70g、炒白芥子35-45g、甘草20-28g制成;其中,将党参、炙土元、鹿角霜、地龙、红花、炒白芥子、乌梢蛇、甘草分别粉碎,过300目筛,混合均匀成超微细粉;再将熟地、桂枝、肉桂、炙麻黄、丹参、黄芪6味药加其重量和6-8倍的水,煎煮二次,每次1.5小时,合并煎液,浓缩至相对密度为1.20-1.30的浸膏;将上述细粉和浸膏混合在一起,和成药坨,再制成药丸,包装。
2.根据权利要求1所述的治疗硬皮病的中药,其特征在于,由以下药物制成:党参120g、黄芪160g、鹿角霜80g、丹参80g、红花60g、熟地80g、桂枝40g、肉桂40g、炙麻黄40g、炙土元60g、地龙60g、乌梢蛇60g、炒白芥子40g、甘草24g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010566363A CN102000202B (zh) | 2010-11-30 | 2010-11-30 | 一种治疗硬皮病的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010566363A CN102000202B (zh) | 2010-11-30 | 2010-11-30 | 一种治疗硬皮病的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102000202A CN102000202A (zh) | 2011-04-06 |
CN102000202B true CN102000202B (zh) | 2011-12-07 |
Family
ID=43808071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010566363A Expired - Fee Related CN102000202B (zh) | 2010-11-30 | 2010-11-30 | 一种治疗硬皮病的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102000202B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102671164A (zh) * | 2012-05-04 | 2012-09-19 | 成都绿迪科技有限公司 | 一种治疗硬皮症的中成药 |
CN103599320B (zh) * | 2013-08-14 | 2015-09-09 | 南阳理工学院 | 一种治疗系统性硬化病的中药颗粒剂及其制备方法 |
CN105991447A (zh) * | 2015-02-10 | 2016-10-05 | 中兴通讯股份有限公司 | 分段路由标识sid的处理方法及装置 |
CN105106396A (zh) * | 2015-09-30 | 2015-12-02 | 成都倍加特生物科技有限公司 | 一种可有效治疗局限性硬皮病的内服药物及其制备方法 |
CN105169091A (zh) * | 2015-10-30 | 2015-12-23 | 张先雷 | 一种治疗雷诺氏病的中药胶囊 |
CN106362122A (zh) * | 2016-10-27 | 2017-02-01 | 谭奇纹 | 一种治疗局限性硬皮病的中药 |
CN108434322A (zh) * | 2018-05-23 | 2018-08-24 | 史宝柱 | 一种用于治疗硬皮病的组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1264592A (zh) * | 1999-02-26 | 2000-08-30 | 魏鹏 | 治疗鱼鳞病的药物及其制备方法 |
CN1895415A (zh) * | 2006-06-28 | 2007-01-17 | 王军 | 软肤冲剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1304032C (zh) * | 2004-08-23 | 2007-03-14 | 神威药业有限公司 | 一种抗前列腺增生的药物组合物 |
-
2010
- 2010-11-30 CN CN201010566363A patent/CN102000202B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1264592A (zh) * | 1999-02-26 | 2000-08-30 | 魏鹏 | 治疗鱼鳞病的药物及其制备方法 |
CN1895415A (zh) * | 2006-06-28 | 2007-01-17 | 王军 | 软肤冲剂 |
Non-Patent Citations (3)
Title |
---|
檀龙海等.王玉玺教授治疗系统性硬皮病验案2例.《中医药学报》.2006,第34卷(第6期),39-40. * |
熊声忠.治系统性硬皮病方.《健康必读》.1994,(第6期),32. * |
蔡念宁.硬皮病辨治经验概述.《中国中西医结合皮肤性病学杂志》.2009,第8卷(第6期),384-386. * |
Also Published As
Publication number | Publication date |
---|---|
CN102000202A (zh) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102000202B (zh) | 一种治疗硬皮病的中药 | |
CN101181568B (zh) | 一种治骨质增生及关节疼痛的中药制剂 | |
CN102357177B (zh) | 一种治疗更年期综合症的中药 | |
CN103623346A (zh) | 治疗腹部手术后腹胀的中药 | |
CN102028787A (zh) | 一种治疗妇科炎症的药物组合物 | |
CN101062233B (zh) | 一种接骨散及其制备方法 | |
CN104306948A (zh) | 一种治疗痛风性关节炎的药物组合物 | |
CN104352803A (zh) | 一种治疗胃癌的中药制剂 | |
CN103948694A (zh) | 疏风通痹中药及其制备方法 | |
CN105943955A (zh) | 一种用于治疗胃溃疡的中药制剂及制备方法 | |
CN105125667A (zh) | 一种治疗类风湿关节炎的中成药通络伸筋丸 | |
CN105435209A (zh) | 一种治疗荨麻疹的中药组合物 | |
CN105288492A (zh) | 一种用于直肠癌的中药制剂及其制备方法 | |
CN101905000B (zh) | 用于治疗风湿病的产品配方、药丸制作方法以及药酒 | |
CN103191277B (zh) | 一种治疗气滞证型胆结石的中药汤剂 | |
CN104688988A (zh) | 一种治疗肝郁气滞型月经不调的中药组合物 | |
CN103356825B (zh) | 用于早期治疗骨及关节损伤的中药汤剂 | |
CN104352896A (zh) | 一种治疗血管神经性水肿的中药制剂 | |
CN103735778A (zh) | 一种治疗肥胖症的中药组合物 | |
CN104740040A (zh) | 一种治疗月经不调的中药汤剂 | |
CN102228569A (zh) | 一种治疗松皮癣的中成药 | |
CN102362918A (zh) | 一种治疗硬皮病的中成药 | |
CN102872422A (zh) | 一种治疗卵巢癌晚期的中药水丸制剂 | |
CN110882366A (zh) | 一种治疗类风湿关节炎的中药制剂及其制备方法 | |
CN105497400A (zh) | 一种治疗肾虚痰湿型月经过少的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20131130 |